These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
254 related articles for article (PubMed ID: 26026736)
1. Ovarian and cervical cancer patient derived xenografts: The past, present, and future. Boone JD; Dobbin ZC; Straughn JM; Buchsbaum DJ Gynecol Oncol; 2015 Aug; 138(2):486-91. PubMed ID: 26026736 [TBL] [Abstract][Full Text] [Related]
2. Ovarian carcinoma patient derived xenografts reproduce their tumor of origin and preserve an oligoclonal structure. Colombo PE; du Manoir S; Orsett B; Bras-Gonçalves R; Lambros MB; MacKay A; Nguyen TT; Boissière F; Pourquier D; Bibeau F; Reis-Filho JS; Theillet C Oncotarget; 2015 Sep; 6(29):28327-40. PubMed ID: 26334103 [TBL] [Abstract][Full Text] [Related]
3. Establishment of patient-derived cancer xenografts in immunodeficient NOG mice. Chijiwa T; Kawai K; Noguchi A; Sato H; Hayashi A; Cho H; Shiozawa M; Kishida T; Morinaga S; Yokose T; Katayama M; Takenaka N; Suemizu H; Yamada R; Nakamura Y; Ohtsu T; Takano Y; Imai K; Miyagi Y; Nakamura M Int J Oncol; 2015 Jul; 47(1):61-70. PubMed ID: 25963555 [TBL] [Abstract][Full Text] [Related]
4. Colorectal cancer patient-derived xenografted tumors maintain characteristic features of the original tumors. Cho YB; Hong HK; Choi YL; Oh E; Joo KM; Jin J; Nam DH; Ko YH; Lee WY J Surg Res; 2014 Apr; 187(2):502-9. PubMed ID: 24332554 [TBL] [Abstract][Full Text] [Related]
5. The future of patient-derived tumor xenografts in cancer treatment. Sia D; Moeini A; Labgaa I; Villanueva A Pharmacogenomics; 2015; 16(14):1671-83. PubMed ID: 26402657 [TBL] [Abstract][Full Text] [Related]
6. Creation and characterization of a xenograft model for human cervical cancer. Hoffmann C; Bachran C; Stanke J; Elezkurtaj S; Kaufmann AM; Fuchs H; Loddenkemper C; Schneider A; Cichon G Gynecol Oncol; 2010 Jul; 118(1):76-80. PubMed ID: 20441999 [TBL] [Abstract][Full Text] [Related]
7. Advances in patient-derived tumor xenografts: from target identification to predicting clinical response rates in oncology. Rosfjord E; Lucas J; Li G; Gerber HP Biochem Pharmacol; 2014 Sep; 91(2):135-43. PubMed ID: 24950467 [TBL] [Abstract][Full Text] [Related]
8. Establishment and characterization of an ovarian yolk sac tumor patient-derived xenograft model. Luo M; He Y; Xie B; Li S; Gan F; Zhang S; Luo P Pediatr Surg Int; 2021 Aug; 37(8):1031-1040. PubMed ID: 34031745 [TBL] [Abstract][Full Text] [Related]
9. The Application of Patient-Derived Xenograft Models in Gynecologic Cancers. Jiang W; Xie S; Liu Y; Zou S; Zhu X J Cancer; 2020; 11(18):5478-5489. PubMed ID: 32742495 [TBL] [Abstract][Full Text] [Related]
10. The fidelity of cancer cells in PDX models: Characteristics, mechanism and clinical significance. Shi J; Li Y; Jia R; Fan X Int J Cancer; 2020 Apr; 146(8):2078-2088. PubMed ID: 31479514 [TBL] [Abstract][Full Text] [Related]
11. Molecular and clinical implementations of ovarian cancer mouse avatar models. Zayed AA; Mandrekar SJ; Haluska P Chin Clin Oncol; 2015 Sep; 4(3):30. PubMed ID: 26408297 [TBL] [Abstract][Full Text] [Related]
12. Patient-Derived Xenografts of Breast Cancer. Varešlija D; Cocchiglia S; Byrne C; Young L Methods Mol Biol; 2017; 1501():327-336. PubMed ID: 27796962 [TBL] [Abstract][Full Text] [Related]
13. Patient-derived xenograft platform of OSCC: a renewable human bio-bank for preclinical cancer research and a new co-clinical model for treatment optimization. Sun S; Zhang Z Front Med; 2016 Mar; 10(1):104-10. PubMed ID: 26926009 [TBL] [Abstract][Full Text] [Related]
14. [Application and development of patient-derived tumor xenograft model in translational medicine of tumor]. Wang Z; Zhu Z Zhonghua Wei Chang Wai Ke Za Zhi; 2017 May; 20(5):596-600. PubMed ID: 28534338 [TBL] [Abstract][Full Text] [Related]
15. Generation of stable PDX derived cell lines using conditional reprogramming. Borodovsky A; McQuiston TJ; Stetson D; Ahmed A; Whitston D; Zhang J; Grondine M; Lawson D; Challberg SS; Zinda M; Pollok BA; Dougherty BA; D'Cruz CM Mol Cancer; 2017 Dec; 16(1):177. PubMed ID: 29212548 [TBL] [Abstract][Full Text] [Related]
16. Niche-dependent tumorigenic capacity of malignant ovarian ascites-derived cancer cell subpopulations. Katz E; Skorecki K; Tzukerman M Clin Cancer Res; 2009 Jan; 15(1):70-80. PubMed ID: 19118034 [TBL] [Abstract][Full Text] [Related]
17. Establishment and preclinical application of a patient-derived xenograft model for uterine cancer. Jeong SY; Cho YJ; Ryu JY; Choi JJ; Hwang JR; Kim B; Lee YY; Kim HS; Lee JW Gynecol Oncol; 2021 Jul; 162(1):173-181. PubMed ID: 33972086 [TBL] [Abstract][Full Text] [Related]
18. Patient-Derived Tumor Xenografts Are Susceptible to Formation of Human Lymphocytic Tumors. Bondarenko G; Ugolkov A; Rohan S; Kulesza P; Dubrovskyi O; Gursel D; Mathews J; O'Halloran TV; Wei JJ; Mazar AP Neoplasia; 2015 Sep; 17(9):735-741. PubMed ID: 26476081 [TBL] [Abstract][Full Text] [Related]
19. Patient-derived xenograft models of breast cancer and their predictive power. Whittle JR; Lewis MT; Lindeman GJ; Visvader JE Breast Cancer Res; 2015 Feb; 17(1):17. PubMed ID: 25849559 [TBL] [Abstract][Full Text] [Related]
20. Gene expression differences between matched pairs of ovarian cancer patient tumors and patient-derived xenografts. Liu Y; Chanana P; Davila JI; Hou X; Zanfagnin V; McGehee CD; Goode EL; Polley EC; Haluska P; Weroha SJ; Wang C Sci Rep; 2019 Apr; 9(1):6314. PubMed ID: 31004097 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]